CO6541630A2 - THEOBROMINE COMBINATION WITH A DESCONGESTIVO AND ITS USE FOR THE TOS TREATMENT - Google Patents

THEOBROMINE COMBINATION WITH A DESCONGESTIVO AND ITS USE FOR THE TOS TREATMENT

Info

Publication number
CO6541630A2
CO6541630A2 CO12098537A CO12098537A CO6541630A2 CO 6541630 A2 CO6541630 A2 CO 6541630A2 CO 12098537 A CO12098537 A CO 12098537A CO 12098537 A CO12098537 A CO 12098537A CO 6541630 A2 CO6541630 A2 CO 6541630A2
Authority
CO
Colombia
Prior art keywords
theobromine
descongestivo
combination
tos
treatment
Prior art date
Application number
CO12098537A
Other languages
Spanish (es)
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of CO6541630A2 publication Critical patent/CO6541630A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una preparación farmacéutica combinada,con elementos característicos que comprenden teobrominay un descongestivo, para ser usada secuencialmente o enforma separada en terapia, específicamente en la terapiade la tos.A combined pharmaceutical preparation, with characteristic elements comprising theobromine and a decongestant, to be used sequentially or separately in therapy, specifically in cough therapy.

CO12098537A 2009-12-14 2012-06-12 THEOBROMINE COMBINATION WITH A DESCONGESTIVO AND ITS USE FOR THE TOS TREATMENT CO6541630A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0921805.8A GB0921805D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy

Publications (1)

Publication Number Publication Date
CO6541630A2 true CO6541630A2 (en) 2012-10-16

Family

ID=41667045

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12098537A CO6541630A2 (en) 2009-12-14 2012-06-12 THEOBROMINE COMBINATION WITH A DESCONGESTIVO AND ITS USE FOR THE TOS TREATMENT

Country Status (18)

Country Link
EP (1) EP2512464A1 (en)
JP (2) JP2013513651A (en)
CN (2) CN105816462A (en)
AU (1) AU2010332494B2 (en)
BR (1) BR112012014161A2 (en)
CA (1) CA2784214C (en)
CO (1) CO6541630A2 (en)
EC (1) ECSP12012132A (en)
GB (1) GB0921805D0 (en)
IL (1) IL220383A (en)
MX (1) MX343222B (en)
NZ (1) NZ600243A (en)
PE (1) PE20121537A1 (en)
RU (1) RU2564904C2 (en)
SG (2) SG10201408377QA (en)
UA (1) UA105944C2 (en)
WO (1) WO2011073646A1 (en)
ZA (1) ZA201204293B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9407414A (en) * 1993-09-07 1996-11-12 Procter & Gamble Compositions containing a non-steroidal propionic acid anti-inflammatory agent amino acid salt and at least one decongestant an expectorant an antihistamine and an antitussive
HUP9700654A2 (en) 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6417206B1 (en) * 2001-01-26 2002-07-09 Medpointe Healthcare Inc. Antitussive/antihist aminic/decongestant compositions
JP2002308761A (en) * 2001-04-09 2002-10-23 Taisho Pharmaceut Co Ltd Antitussive agent for common cold
JP2003128549A (en) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous membrane
JP4377564B2 (en) * 2002-05-02 2009-12-02 ロート製薬株式会社 Composition for internal use
RU2311919C2 (en) * 2002-12-30 2007-12-10 Каунсел Оф Сайнтифик Энд Индастриал Рисерч Development of anti-coughing and throat softening herbal composition
US20040202677A1 (en) * 2003-04-10 2004-10-14 Hopkins Kevin J. Method of enhanced regional body fat reduction
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
KR20080009994A (en) * 2006-07-25 2008-01-30 안국약품 주식회사 Compositions for treating of cough
CN100518775C (en) * 2007-03-16 2009-07-29 邓丽菊 Medicine composition for treating cough and asthma and preparation thereof

Also Published As

Publication number Publication date
CA2784214C (en) 2018-01-09
ECSP12012132A (en) 2012-09-28
SG181686A1 (en) 2012-07-30
WO2011073646A1 (en) 2011-06-23
MX2012006625A (en) 2012-10-05
SG10201408377QA (en) 2015-02-27
IL220383A0 (en) 2012-08-30
BR112012014161A2 (en) 2016-05-17
PE20121537A1 (en) 2012-12-21
EP2512464A1 (en) 2012-10-24
CN105816462A (en) 2016-08-03
AU2010332494A1 (en) 2012-06-14
RU2564904C2 (en) 2015-10-10
JP2013513651A (en) 2013-04-22
AU2010332494B2 (en) 2015-01-15
NZ600243A (en) 2013-07-26
RU2012129839A (en) 2014-01-27
CA2784214A1 (en) 2011-06-23
ZA201204293B (en) 2013-02-27
GB0921805D0 (en) 2010-01-27
CN102740843A (en) 2012-10-17
JP2016040279A (en) 2016-03-24
UA105944C2 (en) 2014-07-10
MX343222B (en) 2016-10-28
IL220383A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
CL2012003026A1 (en) Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity.
CL2015000294A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an epidermal growth factor receptor inhibitor and optionally a pi3halpha inhibitor and use in the treatment of a proliferative disease.
CL2012001950A1 (en) Use of a probiotic bacterial strain in the manufacture of a medicament or nutritional composition in humans or animals to alter sleep patterns
CL2013000718A1 (en) An inclusion complex comprising a) a cyclodextrin, b) fulvestrant and c) a carrier; its method of preparation; formulation and dosage form comprising the complex; preparation comprising the complex or formulation; and its use in the treatment of cancer and systemic lupus erythematosus, among other diseases.
GT200800250A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
CL2013003577A1 (en) Use of a pharmaceutical composition comprising panobinostat and ruxolitinib in the prevention and / or treatment of myeloproliferative neoplasms.
BR112013001423A2 (en) method, in vitro method, use and useful kit to perform the method
CO6541638A2 (en) THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE
GT201200304A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
CO6700840A2 (en) Theobromine in combination with an expectorant or mucolytic for use in therapy
CO6541630A2 (en) THEOBROMINE COMBINATION WITH A DESCONGESTIVO AND ITS USE FOR THE TOS TREATMENT
CL2013001564A1 (en) Method to treat overweight or obesity that includes administering naltrexone and bupropion; method to increase the bioavailability of naltrexone and bupropion in a combination therapy; use of naltrexone and bupropion to treat overweight or obesity and increase the bioavailability of these drugs; pharmaceutical composition
CL2014003525A1 (en) Pharmaceutical composition comprising fimasartan, hydrochlorothiazide and a binder; preparation procedure; its use in the treatment of hypertension.
ITTO20040390A1 (en) COMPOSITION, IN PARTICULAR FOR PHARMACEUTICAL USE, WITH ANTIOXIDANT, ANTI-INFLAMMATORY AND IMMUNOSTIMULATING ACTION.
CO6551744A2 (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY
ECSP12011893A (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY
ECSP10010661A (en) DRONEDARONE FOR THE PREVENTION OF CARDIOVERSION
CL2008000965A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN OPIACEAL ANALGESIC, AND ITS USE FOR PAIN TREATMENT.
ECSP12011951A (en) USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR A PARASITARY DISEASE
CL2010001594A1 (en) Use of nifurtimox to prepare a medicine useful in the treatment of diseases caused by trichomonadide.
BR112014007022A8 (en) pharmaceutical composition, method of improving absorption in the small intestine and use of a pharmaceutical composition.
AR067351A1 (en) PICOTAMIDE COMBINATION WITH NAFRONIL
AR061618A1 (en) TEMOZOLOMIDE UNIT DOSAGE FORMS
ECSP12011969A (en) THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE
CL2007003284A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ASSOCIATION OF I) CYCLLOBENZAPRINE, II) ACECLOFENACO AND OPTIONALLY III) EXCIPIENTS; AND ITS USE FOR THE TREATMENT OF PAINFUL MUSCLE DISEASES.